In a recent study published in Nature Communications,Wakita et al.identified BET family protein degrader(BETd)as a novel senolytic drug through high-throughput screening and biofunctional assays.1 BETd preferentially ...In a recent study published in Nature Communications,Wakita et al.identified BET family protein degrader(BETd)as a novel senolytic drug through high-throughput screening and biofunctional assays.1 BETd preferentially eliminated senescent cells by targeting nonhomologus end joining(NHEJ)and autophagy and significantly reduced tumor growth in vivo,suggesting that BETd could be used as a new therapy against cancer and agerelated disease(Fig.1).展开更多
文摘In a recent study published in Nature Communications,Wakita et al.identified BET family protein degrader(BETd)as a novel senolytic drug through high-throughput screening and biofunctional assays.1 BETd preferentially eliminated senescent cells by targeting nonhomologus end joining(NHEJ)and autophagy and significantly reduced tumor growth in vivo,suggesting that BETd could be used as a new therapy against cancer and agerelated disease(Fig.1).
